

## Farxiga® (dapagliflozin) – First-time authorized brand alternative

- On January 3, 2024, <u>Prasco launched</u> an authorized brand alternative of Astra Zeneca's <u>Farxiga</u> (dapagliflozin) tablets.
- Farxiga is approved for the following:
  - To reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression
  - To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure
  - To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus (T2DM) and either established CV disease or multiple CV risk factors
  - As an adjunct to diet and exercise to improve glycemic control in adults with T2DM.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.